Publications by authors named "Victoria M Valvo"
PARP inhibitors sensitize pancreatic ductal adenocarcinoma (PDAC) to radiation by inducing DNA damage and replication stress. These mechanisms also have the potential to enhance radiation-induced type I interferon (T1IFN)-mediated antitumoral immune responses. We hypothesized that the PARP inhibitor olaparib would also potentiate radiation-induced T1IFN to promote antitumor immune responses and sensitization of otherwise resistant PDAC to immunotherapy.
View Article and Find Full Text PDFArticle Synopsis
- Radiotherapy is the main treatment for a deadly type of brain cancer in kids called diffuse midline glioma (DMG), which has a special genetic mutation (H3K27M).
- Researchers found that this mutation makes the tumors weaker against radiation when combined with a medicine called PARP inhibitor (like olaparib), which can help fight the cancer.
- The study showed that using PARP inhibitors with radiotherapy also boosts the immune system, allowing it to attack the cancer cells better, which could be an important new treatment for kids with DMG.
Article Synopsis
- Radiotherapy can trigger a type I interferon-mediated immune response, which may be strengthened by a new ATM inhibitor, enhancing the body's antitumoral efforts against pancreatic cancer.
- Experiments with the ATM inhibitors AZD1390 and AZD0156 revealed that they boost radiation-induced type I interferon expression through specific immune signaling pathways.
- In mouse models, the combination of ATM inhibitors and radiotherapy improved immune responses, leading to better tumor control, increased CD8+ T cell activity, and the potential for effective systemic treatments against other tumors outside the radiation zone.